-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 4, 3SBio announced that its subsidiary, 3SBio Guojian, signed a license agreement to use its research and development product 609A (anti-PD-1 humanized monoclonal antibody injection) for the global immuno-oncology combination therapy syncrovax™.
Rights are licensed to Syncromune, Inc.
, USA
.
According to the agreement, Sunshine Guojian is expected to receive hundreds of millions of dollars in upfront payments, milestone payments and other incentives based on 609A's clinical value prospects, important regulatory and sales milestones, and other commercialization values
.
In fact, in recent years, domestic PD-1 products are speeding up to go overseas.
In addition to 3SBio, PD-1/L1 developed by Livzon mAb, Innovent Bio, BeiGene, CStone Pharmaceuticals and other companies have also gone overseas one after another
.
In this regard, the industry believes that this is due to the continuous breakthrough of domestic pharmaceutical companies in the field of PD-1 in recent years.
It is understood that the PD-1 market has been highly concerned by the majority of industry insiders in recent years
.
At present, under the background of accelerated innovation of domestic pharmaceutical companies, China has become a hot spot for PD-1 investment and research and development.
Nearly half of the world's PD-1 is developed or jointly developed by Chinese companies
.
According to data, as of February 2021, there are 154 PD-1 mAbs under research in the world, of which 85 of the 154 PD-1s in the world are developed or jointly developed by Chinese companies, accounting for 55%
.
In this context, the industry expects that there will be 15 PD-1 mAbs on the domestic market in the next 2 to 3 years
.
It is worth noting that with the increasing number of companies entering the PD-1 market, the competition in this field is also becoming more and more fierce
.
It is reported that there are currently as many as 6 domestic PD-1s listed in China, namely Hengrui's camrelizumab, BeiGene's tislelizumab, Innovent's sintilimab, Jun Shibi's toripalimab, Kangfang Bio's piamplimumab and Yuheng Bio's sapalimab, of which the latter two are newly approved products in 2021, while the first four are Has entered medical insurance through price reduction
.
After many drugs entered the medical insurance, PD-1 has also entered the era of "annual fee of ten thousand yuan"
.
It is understood that the newly listed Kangfang Bio/Chia Tai Tianqing's piamplimumab, under the conditions of charitable donations and other conditions, has reduced the annual cost to 19,500 yuan per year
.
At present, in addition to the fierce market competition and the sharp drop in drug prices, PD-1 new drug research is gradually repeated and homogenized, and the pressure of centralized procurement competition is increasing, all of which continue to intensify the "involution of the PD-1 market".
"
.
In this context, pharmaceutical companies have begun to take various new actions in order to break through
.
Specifically, pharmaceutical companies are mainly making efforts in two aspects
.
First of all, in terms of indications, both domestic pharmaceutical companies and foreign manufacturers are not satisfied with the currently approved indications and are still vigorously conducting research
.
For example, Innovent announced recently that the National Medical Products Administration (NMPA) has officially accepted the innovative PD-1 inhibitor Dabosu® (sintilimab injection) combined with bevacizumab and chemotherapy for the treatment of transepidermal growth A New Indication Application (sNDA) for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR gene mutation positive for factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
.
This is the seventh indication for the drug application
.
Second, pharmaceutical companies are constantly improving their commercialization capabilities
.
In addition to developing the primary medical market and drug combination therapy based on PD-1, "going overseas" has also become a layout strategy adopted by many companies
.
Rights are licensed to Syncromune, Inc.
, USA
.
According to the agreement, Sunshine Guojian is expected to receive hundreds of millions of dollars in upfront payments, milestone payments and other incentives based on 609A's clinical value prospects, important regulatory and sales milestones, and other commercialization values
.
In fact, in recent years, domestic PD-1 products are speeding up to go overseas.
In addition to 3SBio, PD-1/L1 developed by Livzon mAb, Innovent Bio, BeiGene, CStone Pharmaceuticals and other companies have also gone overseas one after another
.
In this regard, the industry believes that this is due to the continuous breakthrough of domestic pharmaceutical companies in the field of PD-1 in recent years.
It is understood that the PD-1 market has been highly concerned by the majority of industry insiders in recent years
.
At present, under the background of accelerated innovation of domestic pharmaceutical companies, China has become a hot spot for PD-1 investment and research and development.
Nearly half of the world's PD-1 is developed or jointly developed by Chinese companies
.
According to data, as of February 2021, there are 154 PD-1 mAbs under research in the world, of which 85 of the 154 PD-1s in the world are developed or jointly developed by Chinese companies, accounting for 55%
.
In this context, the industry expects that there will be 15 PD-1 mAbs on the domestic market in the next 2 to 3 years
.
It is worth noting that with the increasing number of companies entering the PD-1 market, the competition in this field is also becoming more and more fierce
.
It is reported that there are currently as many as 6 domestic PD-1s listed in China, namely Hengrui's camrelizumab, BeiGene's tislelizumab, Innovent's sintilimab, Jun Shibi's toripalimab, Kangfang Bio's piamplimumab and Yuheng Bio's sapalimab, of which the latter two are newly approved products in 2021, while the first four are Has entered medical insurance through price reduction
.
After many drugs entered the medical insurance, PD-1 has also entered the era of "annual fee of ten thousand yuan"
.
It is understood that the newly listed Kangfang Bio/Chia Tai Tianqing's piamplimumab, under the conditions of charitable donations and other conditions, has reduced the annual cost to 19,500 yuan per year
.
At present, in addition to the fierce market competition and the sharp drop in drug prices, PD-1 new drug research is gradually repeated and homogenized, and the pressure of centralized procurement competition is increasing, all of which continue to intensify the "involution of the PD-1 market".
"
.
In this context, pharmaceutical companies have begun to take various new actions in order to break through
.
Specifically, pharmaceutical companies are mainly making efforts in two aspects
.
First of all, in terms of indications, both domestic pharmaceutical companies and foreign manufacturers are not satisfied with the currently approved indications and are still vigorously conducting research
.
For example, Innovent announced recently that the National Medical Products Administration (NMPA) has officially accepted the innovative PD-1 inhibitor Dabosu® (sintilimab injection) combined with bevacizumab and chemotherapy for the treatment of transepidermal growth A New Indication Application (sNDA) for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR gene mutation positive for factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
.
This is the seventh indication for the drug application
.
Second, pharmaceutical companies are constantly improving their commercialization capabilities
.
In addition to developing the primary medical market and drug combination therapy based on PD-1, "going overseas" has also become a layout strategy adopted by many companies
.
